+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

O

Actively Recruiting

This research aims to observe the long-term safety of efgartigimod treatment in adults with generalized myasthenia gravis gMG. It compares patients who are starting or have recently started efgartigimod treatment with those who have not been exposed to efgartigimod and are receiving other standard treatments. The study is non-interventional and prospective, focusing on real-world safety outcomes over an extended period. Participants are divided into two groups one receiving efgartigimod and another receiving other medications for myasthenia gravis. This study does not involve any new treatments being administered as part of the trial but monitors patients during their routine care. The study will continue for up to 10 years to gather long-term safety data. During the study, researchers will track the occurrence of serious infections and other safety concerns in both groups. Patients will be monitored through their regular clinical visits without additional interventions from the study. Participants may be followed for up to 10 years to assess safety outcomes associated with their treatments in everyday medical practice.

Age: 18Years +All Genders
35 locations
R

Actively Recruiting

This trial evaluates the combination of Navlimetostat BMS-986504, pembrolizumab, and chemotherapy compared to placebo with pembrolizumab and chemotherapy in adults with first-line metastatic non-small cell lung cancer having homozygous MTAP deletion. The study is a randomized, double-blind Phase 23 trial sponsored by Bristol-Myers Squibb, aiming to understand treatment benefits in this specific patient group. Participants must have measurable metastatic NSCLC, no prior systemic therapy for metastatic disease, and meet performance status criteria. Participants receive either Navlimetostat plus pembrolizumab and chemotherapy or placebo plus pembrolizumab and chemotherapy. Chemotherapy may include drugs such as cisplatin, carboplatin, pemetrexed, paclitaxel, or nab-paclitaxel, given on specified days at specified doses. Treatment is administered in the first-line metastatic setting, with detailed dosing and combinations determined by study protocols. Randomization assigns participants to one of multiple arms to compare the investigational combination against placebo. Throughout the study, participants are monitored for progression-free survival up to 2 years and 5 years, overall survival up to 5 years, as well as response rates and safety outcomes including adverse events and laboratory abnormalities. Assessments follow RECIST v1.1 criteria with independent and investigator reviews. Safety monitoring includes tracking serious adverse events and treatment-related side effects up to 90 days after treatment ends. The study duration extends to the primary completion date in August 2031, with ongoing evaluations for up to 5 years post-treatment.

Age: 18Years +All GendersPhase 2Phase 3
321 locations
G

Actively Recruiting

This research aims to gather a large group of patients diagnosed with BCR-ABL 1-negative myeloid neoplasms, classified according to WHO 20082016 standards. The study focuses on collecting detailed clinical, biological, and quality-of-life data to better understand disease characteristics, outcomes, and potential prognostic markers. It is an observational registry conducted by the University of Ulm to improve knowledge about this condition over time. Participants in this registry will provide various biological samples, such as bone marrow aspirate, peripheral blood, plasma, buccal swabs, and occasionally skin biopsies. These samples will be used for morphological and genetic analysis. The study does not involve any experimental treatments but collects comprehensive data and samples to assess disease features and clinical outcomes. Throughout the study, researchers will collect clinical information using a defined catalog of relevant variables and assess quality of life with specific symptom assessment forms. They will track outcomes including treatment decisions, responses, overall survival, progression-free survival, and duration of response for up to 25 years. This long-term follow-up allows detailed monitoring of patient health and disease progression.

Age: 18Years +All Genders
30 locations
N

Actively Recruiting

Immune thrombocytopenia ITP is a rare blood disorder caused by an autoimmune condition that reduces platelet counts, increasing the risk of bleeding or prolonged bleeding. New treatments for ITP have emerged recently, but existing clinical studies are limited in their applicability to everyday patient care due to strict criteria. This registry aims to collect real-world clinical data and biospecimens from patients with various types of ITP to improve understanding of diagnosis, therapy, and patient outcomes in routine treatment. The registry includes patients diagnosed with primary or secondary ITP who consent to participate. Data collection occurs at defined points in the disease course either prospectively or retrospectively up to 12 months after diagnosis, provided continuous documentation is available. Biospecimens are collected and stored systematically to support research. Clinical information collected includes disease characteristics, treatment types, complications, quality of life, fatigue scores, and survival data over a follow-up period of up to 5 years. Participants provide clinical data and biosamples at enrollment, then again at 6 months and annually for up to 5 years. Assessments include platelet counts, bleeding and thromboembolic events, laboratory markers such as specific antibodies, and patient-reported outcomes like quality of life and fatigue. The study gathers epidemiological data on incidence, age, sex distribution, causes of ITP, treatment received, and remission status. The registry helps advance knowledge about ITP through long-term monitoring and standardized data collection.

Age: 18Years +All Genders
64 locations
S

Actively Recruiting

This research aims to evaluate the leakage rate of ileo-colic anastomosis within the first 30 days after surgery in patients undergoing right hemicolectomy for colon cancer. Specifically, it compares the leakage rate using MonoPlus suture material to rates reported in literature for handsewn or stapled-handsewn anastomosis. The study focuses on patients treated with elective colectomy and local curative intent where primary anastomosis is performed without protective stoma. Anastomosis leakage is a key concern as it can cause significant complications post-surgery. Participants will undergo either open or laparoscopic right hemicolectomy or extended right hemicolectomy, followed by ileo-colic anastomosis construction using MonoPlus suture material. The anastomosis may be completely hand-sewn or partially sutured combined with stapling. The study observes surgical approaches including conversions between open and laparoscopic surgery. The main focus is on assessing the leakage rate and other surgical outcomes related to this suture material. During the study, patients will be monitored for anastomosis leakage up to 30 days after surgery. Additional evaluations include complication rates at discharge, 30 days, and one year postoperatively, mortality rates, surgical site infections, length of hospital stay, handling of the suture material during surgery, patient satisfaction, quality of life assessments, bowel function, and hernia occurrence up to 12 months. Participants will provide informed consent and data protection agreements before enrollment, and their health and recovery will be closely followed throughout the observation period.

Age: 18Years +All Genders
4 locations
S

Actively Recruiting

Schizophrenia is a severe mental disorder with significant human and societal costs. Approximately 15-30% of patients do not respond to all known antipsychotic treatments, including clozapine, which is considered the current gold-standard for treatment-resistant cases. This trial aims to evaluate whether adding maintenance electroconvulsive therapy mECT to clozapine treatment improves outcomes for patients who have already responded to an initial course of routine ECT. The goal is to determine if mECT can delay relapse or increase the number of relapse-free patients compared to clozapine treatment alone in clozapine-resistant schizophrenia CRS.

Age: 18Years - 75YearsAll GendersPhase Not Applicable
14 locations
O

Actively Recruiting

Researchers are conducting a prospective, non-interventional study called PETRICHOR in Germany to observe adults with severe chronic rhinosinusitis with nasal polyps CRSwNP whose condition is not well controlled by systemic corticosteroids or surgery. The study focuses on patients newly starting treatment with subcutaneous tezepelumab as part of their routine medical care. Treatment decisions are made between patients and their doctors independently of the study. Participants receive tezepelumab following the European product guidelines during their usual clinical visits. No extra diagnostic or monitoring tests are performed beyond standard care. Data are collected at the beginning and throughout routine visits over a period of up to 104 weeks to understand real-world outcomes. Participants will continue their regular clinical visits during the study, where researchers gather information on symptoms using patient questionnaires like the SNOT-22 and other assessments related to nasal polyps, smell loss, and corticosteroid use. The main focus is the change in sino-nasal symptoms over time. Safety and treatment responses are tracked throughout routine care visits for up to two years.

Age: 18Years - 130YearsAll Genders
19 locations
R

Actively Recruiting

Researchers are conducting a registry study involving adult patients diagnosed with acute myeloid leukemia AML and related myeloid neoplasms, including newly diagnosed or relapsedrefractory cases. The study aims to collect comprehensive data on patient characteristics, family history, biological disease profiles, and clinical outcomes. It also focuses on analyzing disease-related genetic markers and the impact of measurable residual disease MRD using various methods. The study does not involve specific treatments but collects data and biological samples such as bone marrow, blood, plasma, and normal tissue including skin biopsies and other specimens. This observational study enrolls patients from around 80 to 90 sites in Germany and Austria. Patients treatment responses, decisions, and outcomes are tracked over time. Participants are observed for up to 10 years, during which researchers gather information on treatment response, survival, relapse rates, quality of life, and genetic markers. The study includes assessments of event-free survival, relapse-free survival, cumulative incidence of relapse and death, and overall survival. Patient consent is required for registration, data storage, and biobanking of specimens for analysis throughout the observation period.

Age: 18Years +All Genders
94 locations